PURPOSE: Patients with cancer who graciously consent for autopsy represent an invaluable resource for the study of cancer biology. To advance the study of tumor evolution, metastases, and resistance to treatment, we developed a next-generation rapid autopsy program integrated within a broader precision medicine clinical trial that interrogates pre- and postmortem tissue samples for patients of all ages and cancer types. MATERIALS AND METHODS: One hundred twenty-three (22%) of 554 patients who consented to the clinical trial also consented for rapid autopsy. This report comprises the first 15 autopsies, including patients with metastatic carcinoma (n = 10), melanoma (n = 1), and glioma (n = 4). Whole-exome sequencing (WES) was performed on frozen autopsy tumor samples from multiple anatomic sites and on non-neoplastic tissue. RNA sequencing (RNA-Seq) was performed on a subset of frozen samples. Tissue was also used for the development of preclinical models, including tumor organoids and patient-derived xenografts. RESULTS: Three hundred forty-six frozen samples were procured in total. WES was performed on 113 samples and RNA-Seq on 72 samples. Successful cell strain, tumor organoid, and/or patient-derived xenograft development was achieved in four samples, including an inoperable pediatric glioma. WES data were used to assess clonal evolution and molecular heterogeneity of tumors in individual patients. Mutational profiles of primary tumors and metastases yielded candidate mediators of metastatic spread and organotropism including CUL9 and PIGM in metastatic ependymoma and ANKRD52 in metastatic melanoma to the lung. RNA-Seq data identified novel gene fusion candidates. CONCLUSION: A next-generation sequencing-based autopsy program in conjunction with a pre-mortem precision medicine pipeline for diverse tumors affords a valuable window into clonal evolution, metastasis, and alterations underlying treatment. Moreover, such an autopsy program yields robust preclinical models of disease.
PURPOSE: Patients with cancer who graciously consent for autopsy represent an invaluable resource for the study of cancer biology. To advance the study of tumor evolution, metastases, and resistance to treatment, we developed a next-generation rapid autopsy program integrated within a broader precision medicine clinical trial that interrogates pre- and postmortem tissue samples for patients of all ages and cancer types. MATERIALS AND METHODS: One hundred twenty-three (22%) of 554 patients who consented to the clinical trial also consented for rapid autopsy. This report comprises the first 15 autopsies, including patients with metastatic carcinoma (n = 10), melanoma (n = 1), and glioma (n = 4). Whole-exome sequencing (WES) was performed on frozen autopsy tumor samples from multiple anatomic sites and on non-neoplastic tissue. RNA sequencing (RNA-Seq) was performed on a subset of frozen samples. Tissue was also used for the development of preclinical models, including tumor organoids and patient-derived xenografts. RESULTS: Three hundred forty-six frozen samples were procured in total. WES was performed on 113 samples and RNA-Seq on 72 samples. Successful cell strain, tumor organoid, and/or patient-derived xenograft development was achieved in four samples, including an inoperable pediatric glioma. WES data were used to assess clonal evolution and molecular heterogeneity of tumors in individual patients. Mutational profiles of primary tumors and metastases yielded candidate mediators of metastatic spread and organotropism including CUL9 and PIGM in metastatic ependymoma and ANKRD52 in metastatic melanoma to the lung. RNA-Seq data identified novel gene fusion candidates. CONCLUSION: A next-generation sequencing-based autopsy program in conjunction with a pre-mortem precision medicine pipeline for diverse tumors affords a valuable window into clonal evolution, metastasis, and alterations underlying treatment. Moreover, such an autopsy program yields robust preclinical models of disease.
Authors: Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo Journal: Genome Res Date: 2010-07-19 Impact factor: 9.043
Authors: Jianmin Wang; Charles G Mullighan; John Easton; Stefan Roberts; Sue L Heatley; Jing Ma; Michael C Rusch; Ken Chen; Christopher C Harris; Li Ding; Linda Holmfeldt; Debbie Payne-Turner; Xian Fan; Lei Wei; David Zhao; John C Obenauer; Clayton Naeve; Elaine R Mardis; Richard K Wilson; James R Downing; Jinghui Zhang Journal: Nat Methods Date: 2011-06-12 Impact factor: 28.547
Authors: Rajal B Shah; Rohit Mehra; Arul M Chinnaiyan; Ronglai Shen; Debashis Ghosh; Ming Zhou; Gary R Macvicar; Soorynarayana Varambally; Jason Harwood; Tarek A Bismar; Robert Kim; Mark A Rubin; Kenneth J Pienta Journal: Cancer Res Date: 2004-12-15 Impact factor: 12.701
Authors: Francesca Demichelis; Heidi Greulich; Jill A Macoska; Rameen Beroukhim; William R Sellers; Levi Garraway; Mark A Rubin Journal: Nucleic Acids Res Date: 2008-02-27 Impact factor: 16.971
Authors: Loredana Puca; Katie Gavyert; Verena Sailer; Vincenza Conteduca; Etienne Dardenne; Michael Sigouros; Kumiko Isse; Megan Kearney; Aram Vosoughi; Luisa Fernandez; Heng Pan; Samaneh Motanagh; Judy Hess; Adam J Donoghue; Andrea Sboner; Yuzhuo Wang; Ryan Dittamore; David Rickman; David M Nanus; Scott T Tagawa; Olivier Elemento; Juan Miguel Mosquera; Laura Saunders; Himisha Beltran Journal: Sci Transl Med Date: 2019-03-20 Impact factor: 17.956
Authors: Katharine Rae Lange; Cheryl Fischer; Prajwal Rajappa; Scott Connors; David Pisapia; Jeffrey P Greenfield; Himisha Beltran; Mark Rubin; Juan Miguel Mosquera; Yasmin Khakoo Journal: Palliat Support Care Date: 2017-09-25
Authors: Jared T Ahrendsen; Mariella G Filbin; Susan N Chi; Peter E Manley; Karen D Wright; Pratiti Bandopadhayay; Jessica R Clymer; Kee Kiat Yeo; Mark W Kieran; Robert Jones; Hart G Lidov; Keith L Ligon; Sanda Alexandrescu Journal: J Neurooncol Date: 2019-09-30 Impact factor: 4.130
Authors: Verena Sailer; Kenneth Wa Eng; Tuo Zhang; Rohan Bareja; David J Pisapia; Alexandros Sigaras; Bhavneet Bhinder; Alessandro Romanel; David Wilkes; Evan Sticca; Joanna Cyrta; Rema Rao; Sheena Sahota; Chantal Pauli; Shaham Beg; Samaneh Motanagh; Myriam Kossai; Jacqueline Fontunge; Loredana Puca; Hanna Rennert; Jenny Zhaoying Xiang; Noah Greco; Rob Kim; Theresa Y MacDonald; Terra McNary; Mirjam Blattner-Johnson; Marc H Schiffman; Bishoy M Faltas; Jeffrey P Greenfield; David Rickman; Eleni Andreopoulou; Kevin Holcomb; Linda T Vahdat; Douglas S Scherr; Koen van Besien; Christopher E Barbieri; Brian D Robinson; Howard Alan Fine; Allyson J Ocean; Ana Molina; Manish A Shah; David M Nanus; Qiulu Pan; Francesca Demichelis; Scott T Tagawa; Wei Song; Juan Miguel Mosquera; Andrea Sboner; Mark A Rubin; Olivier Elemento; Himisha Beltran Journal: JCO Precis Oncol Date: 2019-09-20
Authors: Matthew J Mosquera; Sungwoong Kim; Rohan Bareja; Zhou Fang; Shuangyi Cai; Heng Pan; Muhammad Asad; Maria Laura Martin; Michael Sigouros; Florencia M Rowdo; Sarah Ackermann; Jared Capuano; Jacob Bernheim; Cynthia Cheung; Ashley Doane; Nicholas Brady; Richa Singh; David S Rickman; Varun Prabhu; Joshua E Allen; Loredana Puca; Ahmet F Coskun; Mark A Rubin; Himisha Beltran; Juan Miguel Mosquera; Olivier Elemento; Ankur Singh Journal: Adv Mater Date: 2021-11-14 Impact factor: 32.086